Studies have shown that FXR agonists confer renal protection in obesity-related CKD by downregulating SREBP-1 and upregulating PPARα, CPT1a, and PGC-1α [64]. This evidence concerns the gene NR1H4 and obesity due to melanocortin 4 receptor deficiency.